

Didier Jutras-Aswad

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/6450759/publications.pdf>

Version: 2024-02-01

85
papers

2,464
citations

361413
20
h-index

214800
47
g-index

92
all docs

92
docs citations

92
times ranked

3151
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	4.5	19
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 299-311.	1.9	5
3	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75
4	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. <i>Psychopharmacology</i> , 2022, 239, 1211-1230.	3.1	8
5	Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 216, 173376.	2.9	7
6	Social Robot Interventions in Mental Health Care and Their Outcomes, Barriers, and Facilitators: Scoping Review. <i>JMIR Mental Health</i> , 2022, 9, e36094.	3.3	22
7	Psychometric properties of the French and English short form of the Protective Behavioural Strategies for Marijuana Scale in Canadian university students. <i>BMJ Open</i> , 2022, 12, e053715.	1.9	1
8	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
9	Experiences and perceptions of nurses participating in an interprofessional, videoconference-based educational programme on concurrent mental health and substance use disorders: a qualitative study. <i>BMC Nursing</i> , 2022, 21, .	2.5	3
10	The Impact of Treatment Orders for Residential Treatment of Comorbid Severe Substance Use Disorders for Youth Suffering from Early Psychosis: a Case Series. <i>International Journal of Mental Health and Addiction</i> , 2021, 19, 2233-2244.	7.4	1
11	Challenging CBD protective effect against THC-related outcomes: a call for robust clinical trials. <i>Addiction</i> , 2021, 116, 207-208.	3.3	4
12	Changes in Alcohol Habits Among Workers During the Confinement of COVID-19: Results of a Canadian Cross-Sectional Survey. <i>Substance Abuse: Research and Treatment</i> , 2021, 15, 117822182110332.	0.9	7
13	Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. <i>Addiction</i> , 2021, 116, 2431-2442.	3.3	30
14	Impact of a videoconferencing educational programme for the management of concurrent disorders on nurses' competency development and clinical practice: protocol for a convergent mixed methods study. <i>BMJ Open</i> , 2021, 11, e042875.	1.9	4
15	Technology-Based Psychological Interventions for Young Adults With Early Psychosis and Cannabis Use Disorder: Qualitative Study of Patient and Clinician Perspectives. <i>JMIR Formative Research</i> , 2021, 5, e26562.	1.4	7
16	Gender-specific associations between psychological distress and injecting risk behaviours among people who inject drugs in Montreal, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103319.	3.3	6
17	A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 779-791.	2.8	12
18	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2021, 46, 2101-2111.	5.4	7

#	ARTICLE	IF	CITATIONS
19	Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. <i>International Journal of Drug Policy</i> , 2021, 94, 103205.	3.3	7
20	Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103439.	3.3	5
21	Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108857.	3.2	1
22	Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. <i>European Neuropsychopharmacology</i> , 2021, 51, 106-131.	0.7	10
23	Effectiveness and experiences of the Extension for Community Healthcare Outcomes (ECHO) Model in developing competencies among healthcare professionals: a mixed methods systematic review protocol. <i>Systematic Reviews</i> , 2021, 10, 313.	5.3	4
24	Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107744.	3.2	19
25	Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. <i>American Journal of Preventive Medicine</i> , 2020, 58, 845-853.	3.0	7
26	Discrete time measures versus trajectories of drinking frequency across adolescence as predictors of binge drinking in young adulthood: a longitudinal investigation. <i>BMJ Open</i> , 2020, 10, e035939.	1.9	3
27	Prevalence, Characteristics, and Management of Chronic Noncancer Pain Among People Who Use Drugs: A Cross-Sectional Study. <i>Pain Medicine</i> , 2020, 21, 3205-3214.	1.9	3
28	Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. <i>Microbial Biotechnology</i> , 2020, 15, 1439-1453.	1.7	5
29	Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. <i>Psychiatry Research</i> , 2020, 286, 112890.	3.3	21
30	Management of psychosis in the context of cannabis use: Beyond the chicken or the egg question. <i>Paediatrics and Child Health</i> , 2020, 25, S5-S6.	0.6	1
31	Assessing the current state of medical education on cannabis in Canada: Preliminary findings from Quebec. <i>Paediatrics and Child Health</i> , 2020, 25, S29-S33.	0.6	7
32	Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. <i>Journal of Dual Diagnosis</i> , 2020, 16, 191-207.	1.2	19
33	A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis. <i>Psychiatry Research</i> , 2020, 288, 112940.	3.3	18
34	The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montréal, Canada. <i>Addiction</i> , 2019, 114, 366-373.	3.3	22
35	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 82-87.	1.9	15
36	Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1413-1422.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montr��al, Canada. <i>Addiction</i> , 2019, 114, 1495-1503.	3.3	5
38	Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada. <i>Addictive Behaviors</i> , 2019, 96, 175-182.	3.0	7
39	Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?. <i>International Journal of Drug Policy</i> , 2019, 72, 69-76.	3.3	19
40	How to help homeless youth suffering from first episode psychosis and substance use disorders? The creation of a new intensive outreach intervention team. <i>Psychiatry Research</i> , 2019, 273, 603-612.	3.3	17
41	Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. <i>Cmaj</i> , 2019, 191, E462-E468.	2.0	24
42	Implementation of a contingency approach for people with co-occurring substance use and psychiatric disorders: Acceptability and feasibility pilot study. <i>Addictive Behaviors Reports</i> , 2019, 10, 100223.	1.9	1
43	Examining the Association Between Psychiatric Disorders and Cocaine Binges: Results From the COSMO Study. <i>Journal of Addiction Medicine</i> , 2018, 12, 136-142.	2.6	3
44	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 69, 21-27.	1.8	22
45	Tranquilizer misuse among active cocaine users: Predictors of initiation. <i>Drug and Alcohol Review</i> , 2018, 37, 520-526.	2.1	5
46	Association between Binge Drug use and Suicide Attempt among People who Inject Drugs. <i>Substance Abuse</i> , 2018, 39, 315-321.	2.3	8
47	Le march�� l��gal du cannabis suite �� sa l��galisation au Canada : pistes de r��flexion pour un encadrement efficace. <i>Canadian Journal of Public Health</i> , 2018, 109, 215-218.	2.3	2
48	A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. <i>International Clinical Psychopharmacology</i> , 2018, 33, 268-273.	1.7	5
49	Examining the link between cocaine bingeing and individual, social and behavioral factors among street-based cocaine users. <i>Addictive Behaviors</i> , 2017, 68, 66-72.	3.0	12
50	Reversing the Atypical Valuation of Drug and Nondrug Rewards in Smokers Using Multimodal Neuroimaging. <i>Biological Psychiatry</i> , 2017, 82, 819-827.	1.3	33
51	Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis. <i>Addictive Behaviors</i> , 2017, 72, 138-143.	3.0	67
52	Cannabis and cue-induced craving in cocaine-dependent individuals: A pilot study. <i>Addictive Behaviors</i> , 2017, 73, 4-8.	3.0	7
53	���� love having benzos after my coke shot���� The use of psychotropic medication among cocaine users in downtown Montreal. <i>International Journal of Drug Policy</i> , 2017, 49, 15-23.	3.3	22
54	Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. <i>International Journal of Drug Policy</i> , 2017, 47, 239-243.	3.3	17

#	ARTICLE	IF	CITATIONS
55	High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. <i>International Journal of Drug Policy</i> , 2017, 47, 61-68.	3.3	24
56	A Functional 3'UTR Polymorphism (rs2235749) of Prodynorphin Alters microRNA-365 Binding in Ventral Striatonigral Neurons to Influence Novelty Seeking and Positive Reward Traits. <i>Neuropsychopharmacology</i> , 2016, 41, 2512-2520.	5.4	15
57	Gambling Problems Among Community Cocaine Users. <i>Journal of Gambling Studies</i> , 2016, 32, 1039-1053.	1.6	11
58	Prevalence and correlates of prescription opioid residue injection. <i>Drug and Alcohol Dependence</i> , 2016, 166, 69-74.	3.2	6
59	Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. <i>Addictive Behaviors</i> , 2016, 62, 54-59.	3.0	12
60	Substance Use and Misuse. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 134-135.	1.9	8
61	Epidemiology of Injection Drug Use. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 136-144.	1.9	31
62	Anxiety, mood disorders and injection risk behaviors among cocaine users: Results from the COSMO study. <i>American Journal on Addictions</i> , 2015, 24, 654-660.	1.4	15
63	Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. <i>Substance Abuse: Research and Treatment</i> , 2015, 9, SART.S25081.	0.9	78
64	Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. <i>Journal of Viral Hepatitis</i> , 2015, 22, 792-799.	2.0	33
65	Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans. <i>Journal of Addiction Medicine</i> , 2015, 9, 204-210.	2.6	94
66	Licit and illicit substance use among people who inject drugs and the association with subsequent suicidal attempt. <i>Addiction</i> , 2015, 110, 1636-1643.	3.3	16
67	Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention. <i>International Journal of Drug Policy</i> , 2015, 26, 970-975.	3.3	9
68	Associations of substance use patterns with attempted suicide among persons who inject drugs: Can distinct use patterns play a role?. <i>Drug and Alcohol Dependence</i> , 2015, 147, 208-214.	3.2	35
69	Cigarette smoking may modify the association between cannabis use and adiposity in males. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 121-127.	2.9	10
70	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. <i>Addiction Science & Clinical Practice</i> , 2015, 10, 6.	2.6	1
71	Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. <i>Neurotherapeutics</i> , 2015, 12, 807-815.	4.4	127
72	Portraying Persons Who Inject Drugs Recently Infected with Hepatitis C Accessing Antiviral Treatment: A Cluster Analysis. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-7.	2.0	2

#	ARTICLE	IF	CITATIONS
73	Sustained Drug Use Changes After Hepatitis C Screening and Counseling Among Recently Infected Persons Who Inject Drugs: A Longitudinal Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 755-761.	5.8	65
74	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. <i>Epilepsia</i> , 2014, 55, 791-802.	5.1	766
75	A case of hypomania during nicotine cessation treatment with bupropion. <i>Addiction Science & Clinical Practice</i> , 2013, 8, 22.	2.6	6
76	Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. <i>Frontiers in Psychiatry</i> , 2013, 4, 109.	2.6	34
77	Treatment of Buprenorphine Precipitated Withdrawal: A Case Report. <i>American Journal on Addictions</i> , 2012, 21, 492-493.	1.4	6
78	The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street drug users. <i>Addiction</i> , 2012, 107, 1318-1327.	3.3	149
79	Cannabis-Dependence Risk Relates to Synergism between Neuroticism and Proenkephalin SNPs Associated with Amygdala Gene Expression: Case-Control Study. <i>PLoS ONE</i> , 2012, 7, e39243.	2.5	34
80	Buprenorphine Plasma Concentration in the Management of Opioid Dependence. <i>American Journal on Addictions</i> , 2011, 20, 304-305.	1.4	0
81	Cannabis Use Correlates of Syringe Sharing among Injection Drug Users. <i>American Journal on Addictions</i> , 2010, 19, 231-237.	1.4	8
82	Psychosis Following Excessive Ingestion of Energy Drinks in a Patient With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 353-353.	7.2	30
83	Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 395-412.	3.2	142
84	Neurobiologie de la toxicomanie: avancées récentes et nouvelles stratégies d'intervention. <i>Drogues, Santé Et Société</i> , 2009, 8, 27-73.	0.1	1
85	Le cannabis et ses effets délirants : pour un débat plus nuancé. <i>Drogues, Santé Et Société</i> , 0, 16, 5-30.		2